Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration combines the drug discovery, clinical development and data science expertise from Johnson with BigHat’s Milliner™ platform to guide the design and selection for high-quality antibodies for multiple Neuroscience therapeutic targets.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $355.0 million
Deal Type : Collaboration
Details : The collaboration aims to discover and develop next-generation therapeutic antibodies in oncology and neuroscience by utilising BigHat's Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $30.0 million
December 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $355.0 million
Deal Type : Collaboration
Lead Product(s) : Antibody
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
BigHat Biosciences Completes First Stage of Research Collaboration with Amgen
Details : Achievement of this first milestone shows that BigHat’s platform has the potential to effectively and efficiently design high-quality therapeutic antibodies. This triggers the initiation of work to create a lead panel of VHH antibodies for patients in ...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : Antibody
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?